亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

伊布替尼 医学 无容量 淋巴瘤 内科学 肿瘤科 慢性淋巴细胞白血病 霍奇金淋巴瘤 癌症 白血病 免疫疗法
作者
Anas Younes,Joshua Brody,Cecilia Carpio,Armando López‐Guillermo,Dina Ben‐Yehuda,Burhan Ferhanoğlu,Arnon Nagler,Muhıt Özcan,Irit Avivi,Francesc Bosch,María Dolores Caballero Barrigón,Andrzej Hellmann,Bryone J. Kuss,D. F. David,Fatih Demırkan,Münci Yağcı,Netanel A. Horowitz,Paula Marlton,Raúl Córdoba,Tomasz Wróbel
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:6 (2): e67-e78 被引量:193
标识
DOI:10.1016/s2352-3026(18)30217-5
摘要

Background Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. Methods We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma. Dose optimisation was investigated using a modified toxicity probability interval design. The primary objective of the part B expansion phase was to establish the preliminary activity (the proportion of patients who achieved an overall response) of the combination of ibrutinib and nivolumab in four cohorts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformation. All participants who received at least one dose of treatment were included in the primary analysis and analyses were done by disease cohort. This trial is registered with ClinicalTrials.gov, number NCT02329847. The trial is ongoing. Findings Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3–4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3–4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3–4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3–4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]). Interpretation The combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to that reported with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The clinical response in patients with Richter's transformation was promising and supports further clinical assessment. Funding Janssen R&D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
红墨发布了新的文献求助10
4秒前
传统的乌龟完成签到 ,获得积分10
6秒前
Yebo完成签到 ,获得积分10
8秒前
无花果的应助被如意的灵阳采纳,获得10
9秒前
9秒前
飘逸问萍完成签到 ,获得积分10
10秒前
荔枝完成签到 ,获得积分10
13秒前
CipherSage的应助被正直的魔镜采纳,获得10
13秒前
14秒前
田様的应助被优雅尔芙采纳,获得10
18秒前
海荷完成签到,获得积分10
19秒前
法兰VA069完成签到 ,获得积分10
20秒前
MaChent完成签到,获得积分10
21秒前
学霸业的应助被koman采纳,获得10
23秒前
学不完了完成签到 ,获得积分10
26秒前
27秒前
28秒前
搜集达人的应助被万寿宫人采纳,获得30
29秒前
34秒前
落后的雨筠完成签到,获得积分10
35秒前
lin完成签到,获得积分10
36秒前
36秒前
BIBIYU完成签到,获得积分10
37秒前
39秒前
40秒前
汤小圆完成签到,获得积分10
41秒前
41秒前
Echo完成签到,获得积分10
41秒前
爆米花的应助被伯赏诗霜采纳,获得10
42秒前
耍酷花卷完成签到,获得积分10
42秒前
45秒前
佳1发布了新的文献求助10
47秒前
自信的寄松完成签到 ,获得积分10
48秒前
姜晔发布了新的文献求助10
48秒前
卢茵完成签到,获得积分10
50秒前
超帅的香露完成签到,获得积分10
54秒前
内向南风完成签到 ,获得积分10
55秒前
Apei完成签到 ,获得积分10
55秒前
Viiigo完成签到,获得积分10
58秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194962
求助须知:如何正确求助?哪些是违规求助? 9580711
关于积分的说明 21872442
捐赠科研通 7794663
什么是DOI,文献DOI怎么找? 3437819
关于科研通互助平台的介绍 2561143
邀请新用户注册赠送积分活动 2484511